U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Jadad AR, Boyle M, Cunningham C, et al. Treatment of Attention-Deficit/Hyperactivity Disorder. Rockville (MD): Agency for Healthcare Research and Quality (US); 1999 Nov. (Evidence Reports/Technology Assessments, No. 11.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Treatment of Attention-Deficit/Hyperactivity Disorder

Treatment of Attention-Deficit/Hyperactivity Disorder.

Show details

Evidence Tables

Evidence Tables A: General Characteristics of All Studies

Evidence Table A1. Where Study Was First Identified

Evidence Table A2. Type of Study

Evidence Table A3. Funding Source (multiple answers possible)

Evidence Table A4. Publication Year

Evidence Table A5. Country of Publication

Evidence Table A6. Number of Authors

Evidence Table A7. Areas Covered (multiple areas possible)

Evidence Table A8. Background of First Author (multiple backgrounds possible)

Evidence Table A9. Number of Research Centers

Evidence Table A10. (Study Duration)

Evidence Table A11. Ethnic Groups

Evidence Table A12. Treatment Setting (more than one setting possible)

Evidence Table A13. Is the Analysis Grouped by Treatment Setting?

Evidence Table A14. Are the Inclusion Criteria Reported?

Evidence Table A15. Are the Exclusion Criteria Reported?

Evidence Table A16. Is the Primary Outcome Stated?

Evidence Table A17. Age of Subjects (more than one age group possible)

Evidence Table A18. Gender of Subjects (more than one gender choice possible)

Evidence Table A19. IQ Considered

Evidence Table A20. Diagnostic Model Used

Evidence Table A21. Comorbid Disorders of Subjects (more than one choice possible)

Evidence Table A22. Who Made the Diagnosis? (more than one choice possible)

Evidence Table A23. Sample Origin (more than one choice possible)

Evidence Table A24. Family Characteristics

Evidence Table A25. Number of Treatment Arms

Evidence Table A26. Monitoring of Treatments

Evidence Table A27. Was Compliance With Treatment Measured?

Evidence Table A28. Scores and Tests

Evidence Table A29. Treatment Described

Evidence Table A30. Is the Intended Allocation to Treatment Group Concealed From the Investigator?

Evidence Table A31. Industry Association

Evidence Table A32. Overall Frequencies of Interventions

Evidence Table A33. Overall Outcomes

Evidence Table A34. Overall Frequencies of Tests

Evidence Table B1. Key Characteristics of Studies With Drug vs. Drug Comparisons

Evidence Table B2. Total Number of Characteristics Checked for Drug vs. Drug Comparisons1

Evidence Table B3. Description of Characteristics Checked for Drug vs. Drug Comparisons

Evidence Table C1. Key Characteristics of Studies with Drug vs. Nondrug Comparisons

Evidence Table C2. Total Number of Characteristics Checked for Drug vs. Nondrug Comparisons1

Evidence Table C3. Description of Characteristics Checked for Drug vs. Nondrug Comparisons

Evidence Table D1. Key Characteristics of Studies with Combination Therapy

Evidence Table D2. Total Number of Characteristics Checked for Combination Therapy Comparisons1

Evidence Table D3. Description of Characteristics Checked for Combination Therapy Comparisons

Evidence Table E1. Key Characteristics of Studies Comparing Tricyclic Antidepressants vs. Placebo

Evidence Table E2. Total Number of Characteristics Checked for Studies Evaluating Tricyclic Antidepressants vs. Placebo1

Evidence Table E3. Description of Characteristics Checked for Studies Evaluating Tricyclic Antidepressants vs. Placebo

Evidence Table F1. Key Characteristics of Studies With Long-term Therapy

Evidence Table F2. Total Number of Characteristics Checked for Studies Evaluating Long-term Therapy1

Evidence Table F3. Description of Characteristics Checked for Studies Evaluating Long-term Therapy

Evidence Table G1. Key Characteristics of Studies in Adults

Evidence Table G2. Total Number of Characteristics Checked for Studies in Adults1

Evidence Table G3. Description of Characteristics Checked for Studies in Adults

Evidence Table H1a. Key Characteristics of Studies with Adverse Effects Focusing on Sleep Disorders

Evidence Table H1b. Key Characteristics of Studies with Adverse Effects Focusing on Headaches

Evidence Table H1c. Key Characteristics of Studies with Adverse Effects Focusing on Motor Tics

Evidence Table H1d. Key Characteristics of Studies with Adverse Effects Focusing on Decreased Appetite

Evidence Table H1e. Key Characteristics of Studies with Adverse Effects Focusing on Abdominal Pain

Evidence Table H1f. Key Characteristics of Studies with Adverse Effects Focusing on Irritability

Evidence Table H1g. Key Characteristics of Studies with Adverse Effects Focusing on Nausea

Evidence Table H1h. Key Characteristics of Studies with Adverse Effects Focusing on Fatigue/Tiredness

Evidence Table H2. Total Number of Characteristics Checked for Studies with Adverse Effects1

Evidence Table H3. Total Number of Characteristics Checked for Studies with Adverse Effects

Evidence Table I1. Key Characteristics of Studies with Stimulant vs. Placebo Comparisons

Evidence Table I2. Total Number of Characteristics Checked for Studies Involving MPH vs. Placebo1

Evidence Table I3. Description of Characteristics Checked for Studies Involving MPH vs. Placebo

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...